CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,299,058 | +28.5% | 28,620 | +58.9% | 0.00% | – |
| Q2 2023 | $1,011,246 | +14.4% | 18,013 | -7.8% | 0.00% | – |
| Q1 2023 | $883,791 | -11.2% | 19,540 | -20.2% | 0.00% | -100.0% |
| Q4 2022 | $995,312 | -30.3% | 24,485 | +12.1% | 0.00% | 0.0% |
| Q3 2022 | $1,427,000 | +7.6% | 21,842 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $1,326,000 | +10.7% | 21,828 | +14.3% | 0.00% | 0.0% |
| Q1 2022 | $1,198,000 | -3.7% | 19,089 | +16.2% | 0.00% | 0.0% |
| Q4 2021 | $1,244,000 | -29.9% | 16,421 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $1,775,000 | -49.2% | 15,855 | -26.6% | 0.00% | -50.0% |
| Q2 2021 | $3,495,000 | +80.0% | 21,591 | +35.5% | 0.00% | +100.0% |
| Q1 2021 | $1,942,000 | +33.8% | 15,935 | +68.1% | 0.00% | 0.0% |
| Q4 2020 | $1,451,000 | +330.6% | 9,478 | +135.4% | 0.00% | – |
| Q3 2020 | $337,000 | – | 4,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |